A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Tsuji
Shingo
S
Kawano
Sunao
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D005744:Gastric Acid / Q000378:metabolism; D005745:Gastric Acidity Determination; D006356:Heartburn / Q000175:diagnosis / Q000188:drug therapy*; D016481:Helicobacter Infections; D016480:Helicobacter pylori / Q000302:isolation & purification; D006635:Histamine H2 Antagonists / Q000008:administration & dosage; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010880:Piperidines / Q000008:administration & dosage*; D011379:Prognosis; D054328:Proton Pump Inhibitors; D011725:Pyridines / Q000008:administration & dosage*; D064750:Rabeprazole; D012720:Severity of Illness Index; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D010880:Piperidines; D054328:Proton Pump Inhibitors; D011725:Pyridines; D064750:Rabeprazole; C076948:lafutidine; D009853:Omeprazole